Magicbullet

Magicbullet Therapeutics is a pre-clinical stage biotechnology company developing a new class of targeted medicines based on a proprietary programmable conjugate platform. Founded by Dr. Peter Kim, the former President of Merck Research Laboratories, the company aims to engineer smart delivery vehicles that can transport therapeutic payloads directly to specific cell types. Their technology focuses on peptide-drug conjugates (PDCs), which offer potential advantages over traditional antibody-drug conjugates, such as improved tissue penetration and simplified manufacturing. Magicbullet is currently advancing its internal pipeline with an initial focus on oncology and potential applications in infectious diseases. The company is backed by top-tier venture capital firms, including GV, and operates out of South San Francisco.